ConvaTec stock launches Cure Aqua in North America

Published on 10/04/2026 at 19:45 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

ConvaTec stock was last at GBp 216.60 on October 2, 2026, 16.47 percent below its yearly high. Nine brokers set an average GBp 305.44 target.

Extreme Makroaufnahme der Faser- und Gelstruktur einer Wundauflage — ConvaTec Group Plc GB00BD3VFW73 offenbart Makroaufnahme einer Hydrokolloid-Wundauflage mit feiner Fasern- und Gelstruktur, Illustration mit AI erstellt.

ConvaTec stock (ISIN GB00BD3VFW73) was last at GBp 216.60 on the London Stock Exchange on October 2, 2026, with the quote 16.47 percent below its 52-week high of GBp 259.30. The company launched its Cure Aqua hydrophilic catheter in the United States and Canada on September 28, giving the continence-care business a fresh product milestone, according to FT.com.

Cure Aqua reaches North America

Cure Aqua is a ready-to-use intermittent catheter with a hydrophilic coating, a no-touch handling sleeve and female, male and pediatric options. The product requires no activation step, and the September 28, 2026 launch initially covers the United States and Canada, with further markets planned.

The launch adds a commercial milestone to a portfolio built around chronic-care products rather than a single treatment area. ConvaTec operates across advanced wound care, ostomy care, continence care and infusion care, and the company is a constituent of the FTSE 100, according to Investegate.

Buyback changes voting base

Capital returns remain another measurable part of the story. As of September 30, 2026, ConvaTec had 2,049,789,559 ordinary shares issued and 132,464,819 held in treasury, leaving 1,917,324,740 voting rights, according to Investegate. The announcement also said 488,148 shares bought under the program were still in settlement.

That share-count change matters because the buyback reduces the pool used for voting and can alter the per-share effect of future earnings. It also gives investors a concrete counterweight to the product story: Cure Aqua supports portfolio expansion, while the buyback changes the capital structure.

Consensus target stays above price

Analyst sentiment remains positive but is not uniform in its target level. MarketBeat reported on September 28, 2026, that nine brokers held a Moderate Buy consensus, with eight Buy ratings and one Hold rating. The average 12-month target was GBX 305.44, with recent targets ranging from GBX 270 to GBX 335.

Berenberg cut its target from GBX 340 to GBX 335 while retaining a Buy rating on September 11, 2026, according to MarketBeat. The average consensus target lies 41.02 percent above the October 2 price, a gap that leaves execution and product adoption central to the investment debate.

ConvaTec stock stays below its yearly high

ConvaTec stock was last at GBp 216.60 on the London Stock Exchange on October 2, 2026, at 4:37 p.m. BST, down 0.09 percent from the prior close. The session volume was 12,416,703 shares, while market capitalization stood at GBP 4.2 billion.